Back

Clinical Validation of Segmentation-Based Detection of Glioma Progression

Damasceno, P. F.; Gleason, T.; Hawkins, J.; Luks, T.; Majumdar, S.; Lupo, J.; Crane, J.; Villanueva-meyer, J.

2022-08-21 oncology
10.1101/2022.08.17.22278562 medRxiv
Show abstract

PurposeTo evaluate whether an AI-based method could be used routinely as part of patient care to assist in detecting non-enhancing glioma progression. Materials and MethodsA 3D U-Net trained (n=481) and validated (n=121) to segment post-surgical lower grade gliomas was used to measure tumor volumes over time and assess progression in a clinical test set. Eight prospective and eight retrospective patients (total 72 exams) who were suspected of progression during their routine outpatient imaging were clinically assessed. Gold standards for progression were derived from clinical reports a posteriori using visual read, and radiologists were blinded to the AI decision at time of reporting. ResultsProgression assessments were presented to radiologists via an easy-to-use, interactive, and interpretable environment in under 10 minutes. Combining prospective and retrospective cases, a final sensitivity of 0.72 and specificity of 0.75 was achieved at progression detection. ConclusionsAutomated detection of glioma progression would provide valuable decision support for routine use.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.